{"id":"pyronaridine-artesunate","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pyronaridine is an arylmethanol antimalarial that disrupts parasite DNA and protein synthesis, while artesunate is a semi-synthetic artemisinin derivative that generates free radicals to destroy the parasite. Together, they provide rapid parasite clearance and reduce gametocyte formation, lowering transmission risk. The combination addresses both drug-resistant and drug-sensitive Plasmodium species.","oneSentence":"Pyronaridine artesunate is a fixed-dose combination antimalarial that kills malaria parasites through dual mechanisms: pyronaridine intercalates into parasite DNA while artesunate generates reactive oxygen species that damage parasite structures.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:36:50.697Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Uncomplicated malaria caused by Plasmodium falciparum"},{"name":"Uncomplicated malaria caused by Plasmodium vivax"}]},"trialDetails":[{"nctId":"NCT07060794","phase":"PHASE4","title":"Tafenoquine and ACTs (TADORE- Plus)","status":"NOT_YET_RECRUITING","sponsor":"Menzies School of Health Research","startDate":"2026-06","conditions":"Vivax Malaria","enrollment":507},{"nctId":"NCT07470424","phase":"PHASE1","title":"A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults","status":"NOT_YET_RECRUITING","sponsor":"University of Oxford","startDate":"2026-06-01","conditions":"Malaria","enrollment":24},{"nctId":"NCT07362498","phase":"","title":"Health Systems Implementation and Molecular Surveillance of Multiple First-Line Treatments for Uncomplicated Malaria in Western Kenya","status":"COMPLETED","sponsor":"Strathmore University","startDate":"2020-06-01","conditions":"Malaria Falciparum","enrollment":316},{"nctId":"NCT06962319","phase":"PHASE3","title":"Safety of Antimalarials in the FIRst trimEster","status":"RECRUITING","sponsor":"Liverpool School of Tropical Medicine","startDate":"2025-09-30","conditions":"Malaria, Pregnancy, Malaria, Antepartum, Malaria (Uncomplicated)","enrollment":1510},{"nctId":"NCT05343312","phase":"PHASE4","title":"In Vivo Efficacy of Artemether-Lumefantrine, Amodiaquine-Artesunate, Dihydroartemisinin-Piperaquine, and Pironaridine-Artesunate in Mozambique","status":"COMPLETED","sponsor":"Centro de Investigacao em Saude de Manhica","startDate":"2022-03-16","conditions":"Malaria","enrollment":870},{"nctId":"NCT04532931","phase":"PHASE2","title":"Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19","status":"COMPLETED","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2020-09-03","conditions":"COVID-19","enrollment":192},{"nctId":"NCT05441410","phase":"PHASE1, PHASE2","title":"Comparing Safety and Protective Efficacy of Vaccine Candidate PfSPZ-CVac and MVA ME-TRAP/ ChAd63 ME-TRAP in Adults","status":"NOT_YET_RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2025-06-01","conditions":"Malaria","enrollment":30},{"nctId":"NCT04695197","phase":"PHASE3","title":"Malaria as a Risk Factor for COVID-19 in Western Kenya and Burkina Faso","status":"COMPLETED","sponsor":"Liverpool School of Tropical Medicine","startDate":"2021-01-08","conditions":"Covid-19, Malaria","enrollment":143},{"nctId":"NCT01868438","phase":"PHASE1","title":"Relative Bioavailability of Pyronaridine-artesunate in Tablet and Granule Formulations in Healthy Volunteers","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2013-05","conditions":"Malaria","enrollment":60},{"nctId":"NCT01523002","phase":"PHASE1","title":"Drug Interaction Study of Pyronaridine-artesunate & Metoprolol, & Redosing Study of Pyronaridine-artesunate","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2012-01","conditions":"Malaria","enrollment":56},{"nctId":"NCT05929157","phase":"PHASE1, PHASE2","title":"A Crossover Bioavailability Clinical Trial of Parenteral Pyronaridine and Artesunate","status":"UNKNOWN","sponsor":"Centre de Recherche Médicale de Lambaréné","startDate":"2023-09-01","conditions":"Severe Malarial Treatment","enrollment":12},{"nctId":"NCT05084911","phase":"PHASE3","title":"The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients (Phase3)","status":"COMPLETED","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2021-10-18","conditions":"COVID-19","enrollment":1807},{"nctId":"NCT00682630","phase":"PHASE1","title":"Bioequivalence Trial of Pyronaridine Artesunate To-be-marketed Tablet to the Clinical Trial Reference Tablet","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2007-09","conditions":"Malaria","enrollment":42},{"nctId":"NCT01156389","phase":"PHASE1","title":"Pyronaridine Artesunate-Ritonavir Drug-drug Interaction Study","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2010-07","conditions":"Malaria","enrollment":34},{"nctId":"NCT05633420","phase":"PHASE2","title":"Pilot Clinical Trial to Explore Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients","status":"COMPLETED","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2022-07-24","conditions":"COVID-19","enrollment":20},{"nctId":"NCT04783051","phase":"PHASE3","title":"Comparison of ISTp- PYRAMAX-US-RDT to IPTp-SP to Prevent Malaria in Pregnant Women in DRC (ULTRAPYRAPREG)","status":"COMPLETED","sponsor":"University of Kinshasa","startDate":"2021-05-06","conditions":"Malaria in Pregnancy","enrollment":250},{"nctId":"NCT00331136","phase":"PHASE2","title":"Pyronaridine and Artesunate (3:1) in Children With Acute Uncomplicated Plasmodium Falciparum Malaria","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2006-06","conditions":"Uncomplicated Plasmodium Falciparum Malaria","enrollment":60},{"nctId":"NCT05192265","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Pyronaridine-Artesunate Versus Artemether-Lumefantrine","status":"COMPLETED","sponsor":"University of Ibadan","startDate":"2019-05-20","conditions":"Malaria Fever, Plasmodium Falciparum Malaria, Uncomplicated Malaria","enrollment":172},{"nctId":"NCT05052502","phase":"NA","title":"Targeting High Risk Populations With Enhanced Reactive Focal Mass Drug Administration in Thailand","status":"UNKNOWN","sponsor":"University of California, San Francisco","startDate":"2020-11-01","conditions":"Plasmodium Falciparum Malaria, Plasmodium Vivax Malaria","enrollment":49118},{"nctId":"NCT04265573","phase":"","title":"Feasibility, Acceptability and Costs of a Multiple First-lines Artemisinin-based Combination Therapies","status":"COMPLETED","sponsor":"Groupe de Recherche Action en Sante","startDate":"2018-11-10","conditions":"Malaria","enrollment":150000},{"nctId":"NCT04368910","phase":"PHASE3","title":"Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria","status":"TERMINATED","sponsor":"Medicines for Malaria Venture","startDate":"2007-09-06","conditions":"Malaria","enrollment":30},{"nctId":"NCT00541385","phase":"PHASE3","title":"Pyronaridine Artesunate 3:1 Granule Formulation vs. Coartem© Crushed Tablets in P. Falciparum Malaria Pediatric Patients","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2007-10","conditions":"Malaria","enrollment":535},{"nctId":"NCT00440999","phase":"PHASE3","title":"Pyronaridine Artesunate (3:1) in Children and Adults With Acute Plasmodium Vivax Malaria","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2007-03","conditions":"Malaria","enrollment":456},{"nctId":"NCT00422084","phase":"PHASE3","title":"Pyronaridine Artesunate (3:1) Versus Coartem® in P Falciparum Malaria Patients","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2007-01","conditions":"Malaria","enrollment":1272},{"nctId":"NCT01594931","phase":"PHASE2","title":"Phase II Dose-ranging Study of Pyronaridine/Artesunate in Adults Patients With Plasmodium Falciparum Malaria","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2005-07","conditions":"Plasmodium Falciparum Malaria","enrollment":477},{"nctId":"NCT00403260","phase":"PHASE3","title":"Pyronaridine - Artesunate (3:1) Versus Mefloquine Plus Artesunate in Plasmodium Falciparum Malaria Patients","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2007-01","conditions":"Falciparum Malaria","enrollment":1271},{"nctId":"NCT04701606","phase":"PHASE2, PHASE3","title":"The Safety and Efficacy of Pyronaridine-artesunate (Pyramax® or Artecom®)in COVID-19 Patients","status":"UNKNOWN","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2021-03-29","conditions":"Covid19","enrollment":402},{"nctId":"NCT04475107","phase":"PHASE2","title":"The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients","status":"COMPLETED","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2020-07-09","conditions":"COVID-19","enrollment":113},{"nctId":"NCT04778813","phase":"PHASE4","title":"Evaluation of Three Artemisinin-based Combinations for the Treatment of Uncomplicated Malaria in Childreen in Burkina Faso (CHIMIO2)","status":"UNKNOWN","sponsor":"Centre national de recherche et de formation sur le paludisme","startDate":"2021-06-01","conditions":"Malaria, Burkina Faso","enrollment":1050},{"nctId":"NCT03726593","phase":"PHASE4","title":"Drug Combinations of Atovaquone-Proguanil (AP) With ACT","status":"UNKNOWN","sponsor":"Armed Forces Research Institute of Medical Sciences, Thailand","startDate":"2018-10-04","conditions":"Plasmodium Falciparum Malaria (Drug Resistant)","enrollment":252},{"nctId":"NCT04264130","phase":"PHASE2","title":"Effect of Artemisinin-based Combination Therapies on Schistosomiasis on Malaria Co-infection","status":"COMPLETED","sponsor":"Centre de Recherche Médicale de Lambaréné","startDate":"2018-07-31","conditions":"Schistosomiasis Haematobia","enrollment":54},{"nctId":"NCT04049916","phase":"PHASE2, PHASE3","title":"Pyronaridine-artesunate With Low Dose Primaquine for Preventing P. Falciparum Transmission","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2019-09-12","conditions":"Malaria,Falciparum","enrollment":100},{"nctId":"NCT03814616","phase":"PHASE2","title":"Pyramax in Asymptomatic Carriers of P. Falciparum Monoinfections","status":"UNKNOWN","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2018-10-03","conditions":"Malaria,Falciparum","enrollment":300},{"nctId":"NCT03201770","phase":"PHASE4","title":"Cohort Event Monitoring Study of Pyramax®","status":"COMPLETED","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2017-06-22","conditions":"Malaria,Falciparum","enrollment":8572},{"nctId":"NCT02389439","phase":"PHASE2","title":"Efficacy and Safety of Pyronaridine-artesunate for the Treatment in Uncomplicated Falciparum Malaria","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-03-01","conditions":"Malaria, Falciparum","enrollment":123},{"nctId":"NCT02411994","phase":"PHASE3","title":"Pyronaridine-artesunate and Artemether-lumefantrine for the Treatment of Paediatric Malaria","status":"COMPLETED","sponsor":"Royal Tropical Institute","startDate":"2015-10","conditions":"Malaria","enrollment":197},{"nctId":"NCT01552330","phase":"PHASE1","title":"Pharmacokinetic Study of Primaquine and Pyronaridine-Artesunate in Healthy Subjects","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2012-05","conditions":"Healthy","enrollment":17}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Pyramax"],"phase":"marketed","status":"active","brandName":"Pyronaridine artesunate","genericName":"Pyronaridine artesunate","companyName":"Medicines for Malaria Venture","companyId":"medicines-for-malaria-venture","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pyronaridine artesunate is a small molecule used to treat malaria, specifically falciparum malaria. It is typically administered in combination with other medications, such as low-dose primaquine, for preventing the transmission of P. falciparum.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}